Sangamo BioSciences

Sangamo BioSciences
Public
Industry Biomedicine
Founder Edward O. Lanphier II
Headquarters Richmond, California, USA
Number of employees
 84
Website http://www.sangamo.com

Sangamo BioSciences (NASDAQ: SGMO) is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene.

Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS.[1][2][3] SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect.[4] The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV.[5] Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."[6][7]

References

  1. ↑ "The Man Who Had HIV and Now Does Not". New York Magazine. May 29, 2011.
  2. ↑ "Sangamo's New Drug To Combat AIDS/HIV Seen As A Potential Game-Changer". Forbes. September 26, 2011.
  3. ↑ "Pathway to a Cure: Positive Results Continue for Sangamo’s CCR5 Gene Therapy". AIDSMEDS. March 9, 2012.
  4. ↑ "Sangamo BioSciences Initiates Gene Therapy Trials Toward A Cure For HIV". The AIDS Beacon. January 10, 2012.
  5. ↑ "Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes". Scientific American. March 3, 2011.
  6. ↑ "Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T". PRNewsWire. September 12, 2014. Archived from the original on March 7, 2014. Retrieved March 7, 2014.
  7. ↑ "Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-T" (Press release). Sangamo Biosciences. September 12, 2013. Archived from the original on March 7, 2014. Retrieved March 7, 2014.

External links

This article is issued from Wikipedia - version of the Tuesday, September 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.